New Haven, Connecticut 06519

  • Hyperglycemia


Patients will undergo magnetic resonance spectroscopy (MRS) scanning to noninvasively measure intracerebral and plasma metabolite levels at baseline and following 2 and 4 hours of hyperglycemia. Subjects will also undergo a lumbar puncture at a separate occasion to assess cerebrospinal fluid levels of metabolites.


Inclusion Criteria: - Type 2 DM with HbA1C treated with metformin, sulfonylurea, insulin, or combination OR age-matched, non-diabetic obese (BMI > 30 kg/m^2) OR age-matched lean, healthy control subjects (BMI < 25 kg/m^2) - Age 18-55 - BMI 18-45 kg/m^2 Exclusion Criteria: - Creatinine > 1.5 mg/dL - Hgb < 10 mg/dL - ALT > 2.5 x ULN - Untreated thyroid disease - Uncontrolled Hypertension - Known Neurological Disorders - Untreated Psychiatric Disorders - Malignancy - Bleeding Disorders - Smoking - Current or recent steroid use in last 3 months - Illicit drug use - Pregnancy, actively seeking pregnancy, or breastfeeding - Inability to enter MRI/MRS



Primary Contact:

Principal Investigator
Robert Sherwin, MD
Yale University

Janice Hwang, MD
Phone: 203-785-6222

Backup Contact:


Location Contact:

New Haven, Connecticut 06519
United States

Janice Hwang, MD
Phone: 203-785-6222

Site Status: Recruiting

Data Source:

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.